Tasimelteon: A selective and unique receptor binding profile

Abstract

Hetlioz(®) (tasimelteon) is the first approved treatment in the United States for Non-24-Hour Sleep-Wake Disorder (Non-24). We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes. Results indicate that tasimelteon is a potent Dual… (More)
DOI: 10.1016/j.neuropharm.2014.12.004

Topics

7 Figures and Tables

Slides referencing similar topics